Earnings Call Summary | American Oncology Network(AONC.US) Q4 2023 Earnings Conference
Earnings Call Summary | American Oncology Network(AONC.US) Q4 2023 Earnings Conference
The following is a summary of the American Oncology Network, Inc. (AONC) Q4 2023 Earnings Call Transcript:
以下是美國腫瘤網絡公司（AONC）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
American Oncology Network reported Q4 revenue increase of 7.9% to $324.2 million, primarily due to a 9.5% increase in patient encounters.
There was, however, a decrease in revenue per encounter of 1.8%, causing a $5.6 million decrease in patient revenues.
Cost of revenue also increased by $42 million to $315.6 million due to increased drug and supply costs.
Adjusted EBITDA declined by 38% from $8 million to $5 million due to higher drug costs.
The company saw the year out with a liquidity standing at $105.3 million.
美國腫瘤網絡報告稱，第四季度收入增長7.9％，達到3.242億美元，這主要是由於患者接觸人數增加了9.5％。
但是，每次遭遇的收入下降了1.8％，導致患者收入減少了560萬美元。
由於藥品和供應成本的增加，收入成本也增加了4200萬美元，達到3.156億美元。
由於藥品成本上漲，調整後的息稅折舊攤銷前利潤從800萬美元下降了38％，至500萬美元。
該公司今年的流動性爲1.053億美元。
Business Progress:
業務進展：
AON expanded its presence in markets such as Georgia and Arkansas and ventured into new strategic markets like Texas and Florida.
Fourteen new providers joined the AON platform, raising the number to 20 for the full year.
Implementation has begun on a new clinical trial management system and a new enterprise revenue cycle platform.
The company reported top-line revenues of $1.3 billion, representing a 13% increase and a 7.9% increase in patient visits year-on-year.
AON commemorated its fifth anniversary in September and is poised for a promising 2024.
怡安擴大了在喬治亞州和阿肯色州等市場的影響力，並涉足德克薩斯州和佛羅里達州等新的戰略市場。
十四家新提供商加入了怡安平台，使全年這一數字增加到20家。
新的臨床試驗管理系統和新的企業收入週期平台已開始實施。
該公司公佈的收入爲13億美元，同比增長13％，患者就診量增長7.9％。
怡安在9月慶祝了成立五週年，並準備迎接一個充滿希望的2024年。
More details: American Oncology Network IR
更多詳情： 美國腫瘤網絡 IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。